1. Home
  2. FTHY vs CTNM Comparison

FTHY vs CTNM Comparison

Compare FTHY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Trust High Yield Opportunities 2027 Term Fund

FTHY

First Trust High Yield Opportunities 2027 Term Fund

HOLD

Current Price

$13.59

Market Cap

494.6M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$15.10

Market Cap

489.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTHY
CTNM
Founded
2020
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
494.6M
489.4M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
FTHY
CTNM
Price
$13.59
$15.10
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
83.5K
443.6K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
10.93%
N/A
EPS Growth
N/A
0.46
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.20
$3.72
52 Week High
$14.87
$16.91

Technical Indicators

Market Signals
Indicator
FTHY
CTNM
Relative Strength Index (RSI) 52.70 62.43
Support Level $13.21 $10.86
Resistance Level $13.82 $15.60
Average True Range (ATR) 0.13 1.25
MACD 0.02 0.43
Stochastic Oscillator 56.16 67.33

Price Performance

Historical Comparison
FTHY
CTNM

About FTHY First Trust High Yield Opportunities 2027 Term Fund

FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: